Samya Chakravorty1,2,3,4, Babi Ramesh Reddy Nallamilli5, Satish Vasant Khadilkar6,7,8, Madhu Bala Singla6,7,8, Ashish Bhutada6, Rashna Dastur9, Pradnya Satish Gaitonde9, Laura E Rufibach10, Logan Gloster1,4, Madhuri Hegde4,5. 1. Emory University Department of Pediatrics, Atlanta, GA, United States. 2. Emory University Department of Human Genetics, Atlanta, GA, United States. 3. Division of Neurosciences, Children's Healthcare of Atlanta, Atlanta, GA, United States. 4. School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, United States. 5. PerkinElmer Genomics, Global Laboratory Services, Waltham, MA, United States. 6. Department of Neurology, Bombay Hospital, Mumbai, India. 7. Department of Neurology, Sir J J Group of Hospitals, Grant Medical College, Mumbai, India. 8. Bombay Hospital Institute of Medical Sciences, Mumbai, India. 9. Centre for Advanced Molecular Diagnostics in Neuromuscular Disorders (CAMDND), Mumbai, India. 10. Jain Foundation, Seattle, WA, United States.
Abstract
Objective: Inherited myopathies comprise more than 200 different individually rare disease-subtypes, but when combined together they have a high prevalence of 1 in 6,000 individuals across the world. Our goal was to determine for the first time the clinical- and gene-variant spectrum of genetic myopathies in a substantial cohort study of the Indian subcontinent. Methods: In this cohort study, we performed the first large clinical exome sequencing (ES) study with phenotype correlation on 207 clinically well-characterized inherited myopathy-suspected patients from the Indian subcontinent with diverse ethnicities. Results: Clinical-correlation driven definitive molecular diagnosis was established in 49% (101 cases; 95% CI, 42-56%) of patients with the major contributing pathogenicity in either of three genes, GNE (28%; GNE-myopathy), DYSF (25%; Dysferlinopathy), and CAPN3 (19%; Calpainopathy). We identified 65 variant alleles comprising 37 unique variants in these three major genes. Seventy-eight percent of the DYSF patients were homozygous for the detected pathogenic variant, suggesting the need for carrier-testing for autosomal-recessive disorders like Dysferlinopathy that are common in India. We describe the observed clinical spectrum of myopathies including uncommon and rare subtypes in India: Sarcoglycanopathies (SGCA/B/D/G), Collagenopathy (COL6A1/2/3), Anoctaminopathy (ANO5), telethoninopathy (TCAP), Pompe-disease (GAA), Myoadenylate-deaminase-deficiency-myopathy (AMPD1), myotilinopathy (MYOT), laminopathy (LMNA), HSP40-proteinopathy (DNAJB6), Emery-Dreifuss-muscular-dystrophy (EMD), Filaminopathy (FLNC), TRIM32-proteinopathy (TRIM32), POMT1-proteinopathy (POMT1), and Merosin-deficiency-congenital-muscular-dystrophy-type-1 (LAMA2). Thirteen patients harbored pathogenic variants in >1 gene and had unusual clinical features suggesting a possible role of synergistic-heterozygosity/digenic-contribution to disease presentation and progression. Conclusions: Application of clinically correlated ES to myopathy diagnosis has improved our understanding of the clinical and genetic spectrum of different subtypes and their overlaps in Indian patients. This, in turn, will enhance the global gene-variant-disease databases by including data from developing countries/continents for more efficient clinically driven molecular diagnostics.
Objective: Inherited myopathies comprise more than 200 different individually rare disease-subtypes, but when combined together they have a high prevalence of 1 in 6,000 individuals across the world. Our goal was to determine for the first time the clinical- and gene-variant spectrum of genetic myopathies in a substantial cohort study of the Indian subcontinent. Methods: In this cohort study, we performed the first large clinical exome sequencing (ES) study with phenotype correlation on 207 clinically well-characterized inherited myopathy-suspected patients from the Indian subcontinent with diverse ethnicities. Results: Clinical-correlation driven definitive molecular diagnosis was established in 49% (101 cases; 95% CI, 42-56%) of patients with the major contributing pathogenicity in either of three genes, GNE (28%; GNE-myopathy), DYSF (25%; Dysferlinopathy), and CAPN3 (19%; Calpainopathy). We identified 65 variant alleles comprising 37 unique variants in these three major genes. Seventy-eight percent of the DYSF patients were homozygous for the detected pathogenic variant, suggesting the need for carrier-testing for autosomal-recessive disorders like Dysferlinopathy that are common in India. We describe the observed clinical spectrum of myopathies including uncommon and rare subtypes in India: Sarcoglycanopathies (SGCA/B/D/G), Collagenopathy (COL6A1/2/3), Anoctaminopathy (ANO5), telethoninopathy (TCAP), Pompe-disease (GAA), Myoadenylate-deaminase-deficiency-myopathy (AMPD1), myotilinopathy (MYOT), laminopathy (LMNA), HSP40-proteinopathy (DNAJB6), Emery-Dreifuss-muscular-dystrophy (EMD), Filaminopathy (FLNC), TRIM32-proteinopathy (TRIM32), POMT1-proteinopathy (POMT1), and Merosin-deficiency-congenital-muscular-dystrophy-type-1 (LAMA2). Thirteen patients harbored pathogenic variants in >1 gene and had unusual clinical features suggesting a possible role of synergistic-heterozygosity/digenic-contribution to disease presentation and progression. Conclusions: Application of clinically correlated ES to myopathy diagnosis has improved our understanding of the clinical and genetic spectrum of different subtypes and their overlaps in Indian patients. This, in turn, will enhance the global gene-variant-disease databases by including data from developing countries/continents for more efficient clinically driven molecular diagnostics.
Authors: Marjan Huizing; Goran Rakocevic; Susan E Sparks; Ioanna Mamali; Alexey Shatunov; Lev Goldfarb; Donna Krasnewich; William A Gahl; Marinos C Dalakas Journal: Mol Genet Metab Date: 2004-03 Impact factor: 4.797
Authors: M G Pittis; M Donnarumma; A L E Montalvo; S Dominissini; M Kroos; C Rosano; M Stroppiano; M G Bianco; M A Donati; G Parenti; A D'Amico; G Ciana; M Di Rocco; A Reuser; B Bembi; M Filocamo Journal: Hum Mutat Date: 2008-06 Impact factor: 4.878
Authors: N Deconinck; P Richard; V Allamand; A Behin; P Lafôret; A Ferreiro; A de Becdelievre; C Ledeuil; C Gartioux; I Nelson; R Y Carlier; P Carlier; K Wahbi; N Romero; M T Zabot; F Bouhour; V Tiffreau; A Lacour; B Eymard; T Stojkovic Journal: J Neurol Neurosurg Psychiatry Date: 2014-12-22 Impact factor: 10.154
Authors: G Piluso; L Politano; S Aurino; M Fanin; E Ricci; V M Ventriglia; A Belsito; A Totaro; V Saccone; H Topaloglu; A C Nascimbeni; L Fulizio; A Broccolini; N Canki-Klain; L I Comi; G Nigro; C Angelini; V Nigro Journal: J Med Genet Date: 2005-09 Impact factor: 6.318
Authors: Janice A Dominov; Özgün Uyan; Diane McKenna-Yasek; Babi Ramesh Reddy Nallamilli; Virginie Kergourlay; Marc Bartoli; Nicolas Levy; Judith Hudson; Teresinha Evangelista; Hanns Lochmuller; Martin Krahn; Laura Rufibach; Madhuri Hegde; Robert H Brown Journal: Ann Clin Transl Neurol Date: 2019-03-03 Impact factor: 4.511
Authors: Dimitra G Georganopoulou; Vasilis G Moisiadis; Firhan A Malik; Ali Mohajer; Tanya M Dashevsky; Shirley T Wuu; Chih-Kao Hu Journal: Protein J Date: 2021-06-10 Impact factor: 2.371